ALK and anaplastic large cell lymphoma: Responses to crizotinib have also been reported in patients with anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblastic tumors [5, 6], both of which have a high incidence of ALK rearrangements, especially in children [7].